Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ngm Biopharmaceuticals Inc (NGM)

Ngm Biopharmaceuticals Inc (NGM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,531
  • Shares Outstanding, K 83,462
  • Annual Sales, $ 4,420 K
  • Annual Income, $ -142,380 K
  • 60-Month Beta 1.27
  • Price/Sales 29.48
  • Price/Cash Flow N/A
  • Price/Book 0.86
Trade NGM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.72
  • Most Recent Earnings $-0.33 on 03/11/24
  • Latest Earnings Date 05/02/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +48.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5200 +1.32%
on 03/11/24
1.6300 -5.52%
on 03/27/24
+0.0200 (+1.32%)
since 03/04/24
3-Month
1.1800 +30.51%
on 01/05/24
2.2000 -30.00%
on 02/22/24
+0.3500 (+29.41%)
since 01/04/24
52-Week
0.6002 +156.58%
on 11/17/23
4.6900 -67.16%
on 05/01/23
-2.4200 (-61.11%)
since 04/04/23

Most Recent Stories

More News
NGM Biopharmaceuticals: Q4 Earnings Snapshot

NGM Biopharmaceuticals: Q4 Earnings Snapshot

NGM : 1.5400 (-1.28%)
NGM Biopharmaceuticals: Q3 Earnings Snapshot

NGM Biopharmaceuticals: Q3 Earnings Snapshot

NGM : 1.5400 (-1.28%)
NGM Biopharmaceuticals: Q2 Earnings Snapshot

NGM Biopharmaceuticals: Q2 Earnings Snapshot

NGM : 1.5400 (-1.28%)
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM : 1.5400 (-1.28%)
IMTX : 10.23 (-1.45%)
NGM Biopharmaceuticals: Q1 Earnings Snapshot

NGM Biopharmaceuticals: Q1 Earnings Snapshot

NGM : 1.5400 (-1.28%)
Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADCT : 4.96 (+11.71%)
NGM : 1.5400 (-1.28%)
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

NGM : 1.5400 (-1.28%)
AFMD : 5.23 (-2.61%)
NGM Biopharmaceuticals: Q4 Earnings Snapshot

NGM Biopharmaceuticals: Q4 Earnings Snapshot

NGM : 1.5400 (-1.28%)
Belharra Therapeutics Debuts With $130 Million in Funding

Belharra Therapeutics, Inc. today emerged from stealth mode with a novel photoaffinity-based chemoproteomics platform capable of identifying non-covalent, small molecule drug candidates for any protein....

NGM : 1.5400 (-1.28%)
How Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%

The mean of analysts' price targets for NGM Biopharmaceuticals (NGM) points to a 461.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

NGM : 1.5400 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc....

See More

Key Turning Points

3rd Resistance Point 1.5900
2nd Resistance Point 1.5800
1st Resistance Point 1.5600
Last Price 1.5400
1st Support Level 1.5300
2nd Support Level 1.5200
3rd Support Level 1.5000

See More

52-Week High 4.6900
Fibonacci 61.8% 3.1277
Fibonacci 50% 2.6451
Fibonacci 38.2% 2.1625
Last Price 1.5400
52-Week Low 0.6002

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar